Another Penny Stock Deal Gone Bad: CCAN Acquisition of Hydropothecary is a Bust

Three months after announcing it was acquiring Canadian licensed cannabis producer Hydropothecary, Canadian Cannabis Corp (OTC: CCAN), according to unconfirmed sources, will not be closing the deal.  CCAN is an Ontario-based company incorporated in Delaware.  Hydropothecary, based in Gatineau, is the sole cannabis producer approved by Health Canada operating in Quebec.  The company has a high-end focus, offering four premium brands at $15 per gram.

CCAN had suggested on October 20th that it would pay $6mm in cash as part of a transaction valued at $21.3mm at the time.  The bulk of the deal was in stock, which has declined modestly since the transaction was announced:

ccan chart

CCAN is delinquent on its SEC filings, failing to file any quarterly filings in 2015 after posting the 2014 annual filing in October, six months after it was due. The company had detailed the transaction’s terms in an 8-K filing on October 20th. The Letter of Intent had been scheduled to become definitive by October 31st with the cash paid by January 15th, but CCAN never provided an update to its shareholders.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Breaking News by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter